Teclistamab Enables Kidney Transplant in Patient With Zero Compatibility Odds, Published in NEJM
核心洞察
A 37-year-old dialysis-dependent patient with a cPRA of zero received a successful kidney transplant after 31 weeks of teclistamab therapy, a bispecific antibody originally approved for multiple myeloma (搜索).
The drug achieved a substantial and sustained reduction in HLA antibodies, converting previously unacceptable donor markers into acceptable ones — a feat unattainable with existing desensitization methods.
Published in the New England Journal of Medicine, the case study was led by researchers at the Medical University of Vienna and could herald a paradigm shift in transplant medicine.
A 37-year-old dialysis-dependent patient who had spent more than twelve years on the kidney transplant waiting list with a calculated probability (cPRA) of ever finding a compatible donor of zero has now received a successful transplant, thanks to an innovative treatment strategy repurposing a cancer drug. The case, led by researchers at the Medical University of Vienna and published in the New England Journal of Medicine, represents what experts are calling a potential paradigm shift in transplant medicine.
The patient had developed particularly pronounced HLA sensitization (搜索) following two previous kidney transplants. In HLA sensitization, the immune system produces antibodies against human leukocyte antigens (搜索) — tissue markers on potential donor organs — which dramatically restricts the pool of compatible organs. In this case, the cPRA value, which estimates the likelihood of finding a compatible donor kidney, was calculated at zero. The patient's name had been on the waiting list for more than twelve years while his condition progressively deteriorated.
A cancer drug with a novel mechanism
The drug at the center of this breakthrough is teclistamab, a bispecific antibody currently used to treat multiple myeloma (搜索). Teclistamab specifically eliminates those cells in the blood and bone marrow that produce antibodies against foreign structures. This unique mechanism of action drew the attention of the transplant medicine team led by Georg Böhmig and Martina Schatzl from the Clinical Department of Nephrology and Dialysis at MedUni Vienna.
"During the course of therapy, HLA markers from donor kidneys, against which there had previously been strong antibody reactions, were gradually classified as acceptable," reports lead author Martina Schatzl.
31 weeks to a transplant
Treatment with teclistamab was administered over a period of 31 weeks. The drug achieved a substantial and sustained reduction in antibodies against tissue antigens — a level of desensitization that is not possible with currently available methods. Existing desensitization procedures aim to reduce antibody levels prior to transplantation but are only effective to a limited extent and for a short period. By contrast, teclistamab directly intervenes in antibody production and sustainably reduces the immune response over a longer duration.
Eventually, a suitable organ was found and successfully transplanted. "The patient is doing very well today; his kidney function is excellent, and he no longer needs dialysis," adds study leader Georg Böhmig.
Addressing a significant unmet need
An estimated 20 to 30 percent of patients on the waiting list for donor kidneys are affected by significant HLA sensitization (搜索), some of whom have no realistic chance of receiving a suitable organ. The treatment approach described in this case study could open new prospects for this particularly disadvantaged group.
"This could herald a paradigm shift in transplant medicine and open up new prospects for a group of patients who have been particularly disadvantaged until now," says Böhmig.
Broader implications and next steps
Detailed immunological results from the case study also suggest that the new treatment strategy might be applicable in xenotransplantation — the transplantation of organs from genetically modified pigs — as well as in blood-group-incompatible transplants. Böhmig further notes that extension to other forms of organ transplantation, such as heart transplantation, and use in the post-transplant setting to treat antibody-mediated rejection reactions also seems conceivable.
However, before teclistamab can be adopted in routine clinical practice for transplant desensitization, its benefits and risks must be systematically investigated. A study of this kind is already being planned at MedUni Vienna.